Read the ESC/EAS Guidelines for the management of dyslipidaemias (2019)
© The European Society of Cardiology and the European Atherosclerosis Association 2019. All rights reserved. For permissions please email: email@example.com.
This publication is for personal and educational use only. No commercial use is authorized. No part of this publication or the original ESC/EAS Guidelines from which it is derived may be translated or reproduced in any form without written permission from the ESC. Permission may be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions by the ESC. Sanofi has obtained permission to publish this material and to distribute it to health professionals within France, Spain, IE, Norway, Greece, Croatia, Slovenia, United Kingdom.
The ESC/EAS Guidelines represent the views of the ESC/EAS and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC/EAS is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/EAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC/EAS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. Nor do the ESC/EAS Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
Reproduced from: Mach F, Baigent C, Catapano AL, et al, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Heart Journal 2020; 41 (1): 111–188, doi:10.1093/eurheartj/ehz455. Reproduced with permission of Oxford University Press on behalf the European Society of Cardiology.
Sanofi was not involved in the development of this ESC Guideline and in no way influenced its content.
MAT-XU-2204595 (v3.0) Date of Preparation: October 2023